Clinical Trials | December 30, 2025
Edgewise Therapeutics reports positive updates from HCM drug EDG-7500
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
INOVIO remains confident in the therapy’s benefits and intends to meet with the FDA to discuss maintaining eligibility under this pathway
Harbour BioMed brings advanced antibody discovery platforms to the table
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
The company views ESG reporting as a strategic tool to build trust with clients, investors, regulators, and stakeholders worldwide
Intas becomes the first and only company in India to offer IVF and gynecology therapies with needle-free injections
NGD Infection Prevention was formed to scale the delivery of sequence-based transmission detection
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38
Singlera and Pure Medical will team up with local universities, hospital networks, and national healthcare systems across Western Europe for research studies
Subscribe To Our Newsletter & Stay Updated
